A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

Condition:   Advanced or Metastatic Solid Tumors
Interventions:   Drug: Epacadostat;   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Lirilumab
Sponsor:   Incyte Corporation
Not yet recruiting

http://ift.tt/2jKBGG8